Dr. Jean Bourbeau, McGill University, Montréal, QC
Dr. Wan Tan, University of British Columbia, Vancouver, BC

CanCOLD is the only population-based COPD longitudinal study in the world taking its origin from the Burden of Obstructive Lung Disease (BOLD). No other country than Canada has expanded the cross-sectional/prevalence study and insured a longitudinal design with prospective follow-up and detailed measurements by questionnaires, lung function and exercise, imaging with CTScan and biobank. BOLD/COLD in Canada expanded from Vancouver to four additional cities including Montréal, then in 2009 expanding to nine cities and implementing the longitudinal phase, i.e., CanCOLD. In 2018, the three years prospective follow-up of the CanCOLD subjects has been completed. Results from CanCOLD studies have been published in the most renowned medical journals in the respiratory field (Lancet Respiratory Medicine, AJRCCM, ERJ, Chest, Thorax, etc.). More than 50 collaborative substudies have been accepted in partnership with academia including the CRRN and others with industry. In this presentation, an overview of the impact of CanCOLD to date including the emerging knowledge, insights and discoveries will be presented.

Learning Objectives
At the end of this presentation, attendees will be able to:

  • describe the CanCOLD study and it importance as a COPD cohort;
  • give a summary of the accomplishments and challenges; and
  • give an overview of the impact of CanCOLD to date, i.e. the emerging knowledge, insights and discoveries.